pharma · Hereditary Angioedema · Influenza · BCRX
Biocryst
Biocryst is a pharma organization headquartered in München, DE. It trades on NYSE under ticker BCRX. Primary therapeutic focus areas include Hereditary Angioedema, Influenza, Paroxysmal Nocturnal Hemoglobinuria, Paroxysm
Company details
- Status
- Public
- HQ
- München, DE
- Founded
- 1986
- Employees
- 6
- Programs
- 37
- Drugs
- 17
- Patents
- 72
Quick answer
Biocryst is a pharma organization headquartered in München, DE. It trades on NYSE under ticker BCRX. Primary therapeutic focus areas include Hereditary Angioedema, Influenza, Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Gout. NovaPharmaNews links 37 clinical program(s), 3 drug profile(s), and 72 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (18), phase 3 (10), phase 1 (9).
Company snapshot
Wir bei BioCryst haben uns der Bekämpfung seltener und schwerer Krankheiten angenommen. Unser Ziel ist es, Menschen mit Erkrankungen wie beispielsweise dem Hereditären Angioödem (HAE) ein nahezu normales Leben zu ermöglichen. Um dieses Ziel zu erreichen, entwickeln wir neuartige Therapeutika, welche die Ausprägung der Erkrankung beeinflussen. Unsere Medikamentenentwicklung ist an der Zielstruktur
- 4 approved product(s) across US/EU regulatory metadata.
- 37 active pipeline program(s) linked via ClinicalTrials.gov.
- 72 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Biocryst. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026
- deal
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
- trial_data
BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence
Recent coverage
BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence
BioCryst Pharmaceuticals is presenting new clinical data and real-world evidence for ORLADEYO (berotralstat) in hereditary angioedema. The update matters because it expands the evidence base around an FDA-approved oral prophylactic option for adults and pediatric patients 2 years and older.
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
BioCryst Pharmaceuticals has secured a significant European deal for its rare disease drug, Navenibart, bolstering its portfolio and reaffirming its 2026 financial outlook. This strategic move positions the company for expanded market presence and potential revenue growth.
BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026
BioCryst Pharmaceuticals will present new hereditary angioedema (HAE) data for its oral therapy ORLADEYO® (berotralstat) and its investigational therapy navenibart at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. This presentation highlights BioCryst's ongoing commitment to advancing HAE treatment and understanding.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Biocryst.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Biocryst.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Biocryst?
-
Is Biocryst publicly traded?
-
What drugs does Biocryst develop or market?
-
What are the latest developments for Biocryst?
-
What therapeutic areas does Biocryst focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.